Acelyrin (NASDAQ:SLRN) Stock Rating Upgraded by Wells Fargo & Company

Wells Fargo & Company upgraded shares of Acelyrin (NASDAQ:SLRNFree Report) from an equal weight rating to an overweight rating in a research report sent to investors on Monday morning, Marketbeat.com reports. Wells Fargo & Company currently has $13.00 price objective on the stock.

Separately, HC Wainwright upped their price objective on shares of Acelyrin from $16.00 to $18.00 and gave the stock a buy rating in a research note on Wednesday, May 22nd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $12.80.

Check Out Our Latest Analysis on Acelyrin

Acelyrin Stock Up 0.6 %

SLRN stock opened at $5.13 on Monday. The business’s fifty day simple moving average is $4.33 and its two-hundred day simple moving average is $6.09. Acelyrin has a twelve month low of $3.67 and a twelve month high of $29.88. The firm has a market cap of $508.02 million, a price-to-earnings ratio of -2.12 and a beta of 2.56.

Acelyrin (NASDAQ:SLRNGet Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.57. Research analysts expect that Acelyrin will post -3.33 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its position in Acelyrin by 118.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company’s stock valued at $49,000 after purchasing an additional 3,921 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Acelyrin by 608.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,716 shares of the company’s stock valued at $80,000 after purchasing an additional 9,203 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Acelyrin during the fourth quarter valued at about $84,000. New York State Common Retirement Fund boosted its position in Acelyrin by 84.4% during the fourth quarter. New York State Common Retirement Fund now owns 13,181 shares of the company’s stock valued at $98,000 after purchasing an additional 6,032 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Acelyrin during the fourth quarter valued at about $108,000. 87.31% of the stock is owned by institutional investors.

Acelyrin Company Profile

(Get Free Report)

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.

Featured Stories

Analyst Recommendations for Acelyrin (NASDAQ:SLRN)

Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.